MedTrace Logo

Validation of a Predictive Score of Acute Chest Syndrome

NCT03032055 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-12-13

No results posted yet for this study

Summary

Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).

The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.

Conditions

  • Vaso Occlusive Crisis
  • Acute Chest Syndrome

Sponsors & Collaborators

  • Theravia

    collaborator INDUSTRY

  • Pierre Fabre Laboratories

    collaborator INDUSTRY

  • Soutien aux Actions contre les Maladies du Globule Rouge

    lead OTHER

Principal Investigators

  • BARTOLUCCI Pablo, MD PhD, Pr · APHP, UPEC, INSERM

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03032055 on ClinicalTrials.gov